Updates from AMEC and AstraZeneca

The FTSE 100 was up 75 points on Friday at 6,411. Prudential was the biggest climber, up +5.47% while Aberdeen Asset Management saw the biggest dip, down -1.68%. The week ended with strong rallies from most bourses with the Dow Jones climbing +1.38% to 15,248.

Overnight, Asian stocks continued the bounce with the Nikkei soaring +4.94% to 13,514. %VIRTUAL-SkimlinksPromo%A quiet day for corporate numbers. However a number of contract wins. Engineering company AMEC says it been awarded a two-year contract extension from BG Group to continue to provide engineering, procurement and project management support for BG Group's facilities in the central North Sea.

The contract is valued at around £110 million and scheduled to run through to December 2015. The extension follows on from the original three-year contract award in 2011.

"AMEC has been supporting BG Group with brownfield engineering and construction services since our first contract award in 2006," says Alan Johnstone, managing director of AMEC's brownfield business (Europe).

Next, FTSE 250 construction pslayer Balfour Beatty, has been awarded a contract worth £110 million to construct the 43-storey Providence Tower, a residential scheme for Landor - a wholly owned subsidiary of The Ballymore Group.

The structure will be the tallest building constructed by Balfour Beatty in the UK, says the company. "Providence Tower is a great example of the big, complex building projects where Balfour Beatty excels," says chief exec Andrew McNaughton.

Balfour Beatty recently has its price target snipped by Investec from 190p to 170p in a research note issued to investors on Wednesday.

We finish with AstraZeneca. The pharma giant says it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.

The acquisition, claims AstraZeneca, will give it acess to a potential new treatment for chronic obstructive pulmonary disease (COPD), currently in late-stage development, and inhaler and formulation technology that provides a platform for future combination products.

The deal is worth $560 million plus a deferred consideration of up to $450 million "if specified development and regulatory milestones in respect of any triple combination therapies and selected future products that AstraZeneca develops using Pearl's technology platform are achieved".

Read Full Story